For every tomorrow
CureGBM - Advancing Sonodynamic Therapy for Brain Tumours
Building the European pathway for a treatment that should already exist.
We Are CureGBM
WHO WE ARE
CureGBM is a clinical-stage MedTech company founded by siblings Richard Wakefield and Jane Oberholzer after losing their father to glioblastoma in 2021. We are not a charity.
We are building the commercial, clinical, and regulatory infrastructure to bring Sonodynamic Therapy – a transformative brain tumour treatment – to European patients, in time to make a difference to people with this condition today.
WHAT WE DO
We are advancing Sonodynamic Therapy (SDT) for glioblastoma. SDT uses focused ultrasound to activate 5-ALA, a drug that selectively accumulates in brain tumour cells, causing them to self-destruct while leaving healthy tissue untouched. External Phase 1 studies in the United States have already demonstrated a doubling of median survival in patients with recurrent GBM, with no therapy-related adverse events.
We will run our first non-profit SDT trial in Switzerland at the University Hospital in Bern beginning late 2026.
WHY WE EXIST
The standard of care for GBM has not meaningfully changed in thirty years: surgery, radiotherapy, chemotherapy. The evidence for something better already exists. What has not existed, until now, is a European pathway to reach it. We are building that pathway.
MISSION STATEMENT
CureGBM exists to close the European care gap for brain tumour patients by bringing Sonodynamic Therapy to market. We connect the clinical, regulatory, and commercial infrastructure needed to deliver this transformative treatment to the people who need it, when it can still make a meaningful difference.
Services
Choose your Journey
02
Clinician overview of SDT, its scientific basis, and upcoming clinical trial pathway.
03
CureGBM has a patient advocate, Jane Oberholzer, who will be able to answer any questions you may have about the trial and direct any medical queries to the relevant clinicians involved in the trial.
Announcing
2026 Trial of Sonodynamic Therapy for GBM
Patient-Centric Approach
This safety trial is for people with Glioblastoma (GBM) that have previously been treated with maximal resective surgery, radio- and chemotherapy. Patients must be independent of daily activities, aged over 18 years old, and not part of another research trial / experimental treatment.
Medical Mission
Despite surgery and chemo/ radiotherapy, almost all GBM tumours recur (recGBM), at which point survival drops to just 6-8 months. For children diagnosed with DIPG / DMG, the prognosis is even more devastating – typically no more than 9 months after radiotherapy. Early SDT trials in the USA have shown average survival to double after SDT treatment: to 14 months for recGBM, and 16 months for DIPG / DMG – with no side effects from therapy - even with repeated monthly treatments.
Expertise You Can Trust
We strongly believe outpatient-delivered SDT treatments represent a transformative leap in neuro-oncology - a powerful third-line therapy which could redefine care and restore hope for patients and families facing these relentless diseases.
Enrol Data
The trial will be in Bern, Switzerland starting in 2026. Initial enquiries can be made to the team at CureGBM via the contact form. The information will be held and you will be contacted by the enrollment team from Bern when trial eligibility opens.
Don't miss out on the latest news
News
Our Story. Why CureGBM Exists
Our Story: Why CureGBM Exists Sound kills cancer Jane Oberholzer and her brother Richard founded CureGBM after losing their dad
Explore powerful stories of hope
Patient Stories
Duncan Campbell’s Story
Duncan Campbell’s Story Why We Fight for Better Treatment Access Duncan Campbell was 27 living his best life with his
Voices
Our mission is Personal...
Team
Richard Wakefield
Founder CureGBM
Jane brings a deeply personal and compassionate perspective to CureGBM as its dedicated Patient Advocate. Having lived and worked in both London and Zurich, she balances a demanding career in asset management with a rich family life and active involvement in community philanthropy. Her commitment to CureGBM is rooted in her own experience – when her father was diagnosed with glioblastoma (GBM), she faced the journey with minimal support. Today, she channels that experience into being a steady, empathetic presence for patients and families navigating the same path.
Jane Oberholzer
Patient Advocate CureGBM
Contact us today
For every tomorrow.
Initial enquiries can be made to the team at CureGBM. Fill out the form here.
- UK ⎥ SWITZERLAND ⎥ ITALY